The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis
Rhinitis, Allergic, Perennial
About this trial
This is an interventional treatment trial for Rhinitis, Allergic, Perennial focused on measuring perennial allergic rhinitis
Eligibility Criteria
Inclusion Criteria: A clinical history of perennial allergic rhinitis and a positive skin prick test to dust mite, cockroach, mold, or cat or dog antigens. Willingness of the subject to participate in and complete the study, and the ability to understand the purpose of the trial. Exclusion Criteria: Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease. Women of childbearing potential who are pregnant, trying to become pregnant or nursing a child. Subjects treated with systemic steroids during the previous 30 days. Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 15 days. Subjects treated with oral antihistamines/decongestants during the previous seven days. Subjects treated with topical (intranasal or intraocular) antihistamines/decongestants during the previous 3 days. Subjects treated with immunotherapy who are escalating their dose. Subjects on chronic anti-asthma medications. Subjects with polyps in the nose or a significantly displaced septum. Subjects who have incurred an upper respiratory tract infection within 14 days of the start of the study.
Sites / Locations
- The University of Chicago
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
Fluticasone propionate + Placebo
Fluticasone propionate + Montelukast
Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily) Placebo - 10 mg po daily for 2 weeks
Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily) Montelukast - 10 mg po daily for 2 weeks